TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study presented at a European dermatology meeting found nail lifting and discoloration were more common among GLP-1 receptor agonist users than among non-users with obesity or diabetes. However, an analysis limited to nail problems that began after treatment started found no difference, so the study does not establish that the drugs caused the changes.
A study of 575 GLP-1 receptor agonist users found that nail lifting and discoloration were more common than among a comparison group of people with obesity and/or type 2 diabetes who had never used the drugs. But an analysis restricted to nail problems that began after treatment started found no difference between users and non-users, leaving open whether the medicines played a direct role.
Researchers reported onycholysis—separation of a nail from its nail bed—in 39.3% of GLP-1 users, compared with 8.7% of the 1,329 controls. The study described this as a 4.5-fold higher prevalence among users. Nail discoloration, or dyschromia, was reported by 45.6% of users and 17.0% of controls, a 2.7-fold difference. Fragile nails and ridges or grooves were also more common among users.
Across the groups, 66.3% of users and 52.8% of non-users reported some type of nail disorder, a statistically significant difference. The researchers said associations with onycholysis and discoloration remained in analyses that accounted for factors including age, sex, country and other health conditions. Analyses considering participants’ history of nail problems also continued to show differences.
However, almost half of the people taking GLP-1 drugs said they had nail problems before treatment. When researchers examined only new-onset nail lesions, they found no difference in onycholysis or discoloration between the groups. The study was based on an online survey, and participants’ nails were not examined in person by dermatologists, according to the report.
What the Nail Findings Could Mean
The findings flag a possible issue for patients and clinicians to monitor, but they do not show that GLP-1 medicines cause nails to lift or change color. Nail lifting can have several causes, and the contrast between the overall results and the new-onset analysis makes the association difficult to interpret.
For people taking these drugs, the report does not establish a reason to stop treatment. Joe Tung, a dermatologist at the University of Pittsburgh Medical Center who was not involved in the study, said the results should not alarm people doing well on their medication. He said nail changes should be evaluated by a dermatologist because common causes are often treatable, while the study alone does not justify stopping an otherwise beneficial drug for an appropriate patient.
As an affiliate, we earn on qualifying purchases.
How Researchers Compared Nail Problems
The study recruited participants in France, the United States, Brazil and Mexico. Researchers compared 575 people taking GLP-1 receptor agonists with 1,329 people with obesity and/or type 2 diabetes who had never taken one. The control group was older on average—56.7 years, compared with 45.3 among users—while the sex distribution was roughly even in both groups.
Lead investigator Bianca Maria Piraccini, of the University of Bologna, presented the findings at a meeting of the European Academy of Dermatology and Venereology in Vienna. The research is among the first large-scale analyses of nail and hair effects associated with GLP-1 medicines, according to co-investigator Charles Taieb. Earlier reports of nail changes during treatment had largely been anecdotal, he said.
The study compared groups at one point rather than demonstrating that the medication preceded and caused each reported disorder. The researchers said they considered potential explanations such as other health conditions and prior nail problems. The source report says investigators also sought to rule out causes such as trauma or fungal infection, but the survey-based design and lack of in-person nail examinations limit how firmly causes can be excluded.
“Don’t forget to look at the nails and ask if [nail abnormalities] were present prior to starting the treatment or if the onset was during treatment.”
— Bianca Maria Piraccini
As an affiliate, we earn on qualifying purchases.
Cause and New Cases Remain Unclear
The central uncertainty is whether GLP-1 treatment contributes directly to nail disorders. The higher rates in the full comparison were not reproduced in the analysis of new-onset onycholysis or dyschromia. Prior nail problems were common among users, and differences between the groups—including age and health conditions—may affect comparisons even when statistical adjustments are made.
The study also relied on self-reported information collected online, rather than clinical examinations of participants’ nails. The findings therefore cannot establish when each disorder began or what caused it. Piraccini said the association may lie between the adjusted results and the new-onset analysis; that interpretation remains a hypothesis, not a demonstrated drug effect.
As an affiliate, we earn on qualifying purchases.
Further Studies Needed to Test the Link
Piraccini said the results would prompt the team to conduct more studies. Further research would need to clarify whether nail changes arise after treatment, assess them through clinical examinations, and distinguish a possible medication effect from weight loss, nutrition, underlying conditions and other causes.
For now, the study authors’ practical suggestion is for clinicians to ask about nail health before and during treatment and examine reported changes. Patients who notice lifting, discoloration or other nail problems can seek assessment from a dermatologist; the study does not establish that stopping a GLP-1 medicine is necessary.
As an affiliate, we earn on qualifying purchases.
Key Questions
What nail problems were associated with GLP-1 use in the study?
The study reported higher rates of onycholysis, or nail separation, and dyschromia, or discoloration, among GLP-1 users. Fragility and ridges or grooves were also more common in that group.
Does the study prove GLP-1 drugs cause detached nails?
No. The study found an association in its overall comparison, but an analysis limited to nail problems that began after treatment started found no difference between users and non-users. The results do not prove causation.
How many people took part?
Researchers compared 575 GLP-1 receptor agonist users with 1,329 people with obesity and/or type 2 diabetes who had never used a GLP-1 drug. Participants were recruited in four countries.
Should someone stop taking a GLP-1 medicine because of nail changes?
The study does not establish that stopping treatment is necessary. Tung, a dermatologist not involved in the research, said the findings alone would not justify stopping an otherwise beneficial medication for an appropriate patient. People with nail changes can seek evaluation from a dermatologist.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
